ResearchPod Summary
With the rising threat of multidrug-resistant bacteria, particularly methicillin-resistant Staphylococcus aureus (MRSA), there is a critical need for new antibiotic classes. This study targets the bacterial protein synthesis machinery—specifically the formation of the ternary complex between Elongation Factor Tu (EF-Tu), aminoacyl-tRNA, and GTP. While this is an essential biological step, it currently lacks clinical inhibitors that are both safe and effective.
The researchers developed a high-throughput screening (HTS) assay utilizing Fluorescence Resonance Energy Transfer (FRET) to monitor the interaction between engineered EF-Tu and tRNA. By screening a library of pharmacologically active compounds, they identified (R,R)-tetrahydrochrysene, which they renamed MGC-10, as a potent inhibitor of this ternary complex formation. The team subsequently evaluated MGC-10's activity against various Gram-positive clinical isolates, tested for the development of bacterial resistance, assessed toxicity in mammalian cells, and evaluated its therapeutic potential in a mouse model of skin infection.
MGC-10 demonstrated broad-spectrum inhibitory activity against numerous MRSA strains and other Gram-positive pathogens, with MIC values of 6 μM. A significant advantage is that no resistant strains were identified despite intensive attempts, likely due to the complex nature of the EF-Tu target. While systemic administration in mice revealed toxicity—specifically, the drug accumulated in the liver—the researchers found it highly successful as a topical treatment. In a mouse model of MRSA skin infection, topical application of MGC-10 performed as well as or better than mupirocin, the current standard of care, with no evidence of systemic accumulation.
These results position MGC-10 as a promising candidate for topical treatment of difficult-to-treat, antibiotic-resistant skin infections. Its ability to maintain efficacy against mupirocin-resistant MRSA makes it a valuable potential addition to the clinical toolkit. Furthermore, the FRET-based assay developed here provides a robust framework for identifying additional inhibitors targeting this previously under-explored molecular mechanism in bacterial protein synthesis.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.